Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA issues naming guidance

This article was originally published in The Tan Sheet

Executive Summary

A guidance published Feb. 8 outlines what information FDA needs from manufacturers to evaluate proposed proprietary names to ensure the names do not look or sound like other drug names, which could cause medication errors, according to a Federal Register notice. The 1guidance does not include long-awaited best practices for naming, labeling and packaging drugs or details on a pilot program for evaluating proposed proprietary names, according to the notice. FDA's pilot program to reduce drug name confusion offered firms little reason to participate (2"The Tan Sheet" June 30, 2008). The drug name review process does not apply to monograph drugs but to Rx drugs and OTCs approved through new drug applications, abbreviated NDAs and investigational new drugs

You may also be interested in...

FDA’s Proposed Name Review Pilot Offers Little Reason To Participate

A proposed FDA pilot program that would shift the burden for safety review of proprietary drug names from the agency to industry needs to account for key differences between OTC and Rx products and lacks participation incentives, pharmaceutical researchers say

Sales Already Growing As Vascepa Secures Cardio Approval

Company forecasts 2020 sales as high as $700m after regulator grants broad label.

Another EU MDR Notified Body In The Netherlands

Last week, the European Commission revealed that three more notified bodies had been designated, but their listings had not been made official. Now we learn that one of the three is in the Netherlands as the first listing takes place.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts